HIV vaccine candidate ΔV1gp120 formulated in ALFQA adjuvant augments mucosal immunity in female macaques.

ABSTRACT: Simian or Human immunodeficiency virus (SIV or HIV) vaccines based on V1-deleted envelope virus-like particles, delivered by the DNA/ALVAC platforms, followed by the ΔV1gp120 boost formulated in Alum, protect 50% and 80% of macaques from mucosal infection with SIV_mac251 or Simian-Human immunodeficiency virus, respectively. Adding the Army Liposome Formulation + QS21 (ALFQ) adjuvant to the ΔV1gp120+Alum boost (ALFQA) may enhance protective immune responses. Here, we show that ALFQA protects 58% of female macaques from infection following eleven exposures to SIV_mac251, achieving 79% vaccine efficacy. The ALFQA vaccine regimen augments mucosal CD73⁺CD163⁺ M2-like macrophages and NKp44⁺ innate lymphoid cells (ILCs), while reducing NKG2A

SUBMITTER: Bissa M 

PROVIDER: S-EPMC12480912 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature